The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Borrower

C••••• B••••••••• I••

Drug Discovery & Developmentgroup grade Aoff every schedule since Mar 31, 2023sponsor unattributed

Nothing material in the last 200 days. Last change: 31 Mar 2023, Consensus mark 89¢ on cost, down from 98¢ in Q4 2022.

Mark path, consensus per quarter end
Q4 2022: 98¢Q1 2023: 89¢98¢ · 89¢Q4 2022 to Q1 2023
Principal held
at least $17.5M
sum of BDC pieces, a lower bound
Fair value
$16.3M
89c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Oct 1, 2025
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Mar 31, 2023
Events
2
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2023, folded to one row per lender
LenderExposureCurrent markQoQ change
H••••••• C••••••• I•••$17.5M89¢-9 pts
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
BDCInstrumentPrincipalFair valueRate
H••••••• C••••••• I•••term loan first lien
S••••• S••••••, M••••••• D••• O•••••• 2025, P•••• + 5.00%, F•••• rate 8.25%, 5.50% E••• Fe
$17.5M$16.3M
89c
S+500 bp
Capital structure as the BDCs see it
latest quarter end Mar 31, 2023
FacilityHeldOn costPricingMaturityBDCs
first lien term loan first lien
exited Mar 31, 2023
at least $17.5M89cS+500 bpOct 1, 20251
Through time
the borrower's pieces summed across BDCs, every quarter end
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Mar 31, 20231$17.5M$16.3M89c0
Dec 31, 20221$25.0M$25.2M98c0
What changed
Every change including routine ones
Identity
Group key
C••••• B•••••••••derivedthe codename stem after legal suffixes and deal words
Spellings
1 across 1 BDCderived
Industry
Drug Discovery & Developmentreportedas one filer wrote it